Recursion Pharmaceuticals is a clinical-stage TechBio company that uses automation, high-content cellular imaging, and machine learning to industrialize drug discovery. Following its November 2024 combination with Exscientia, Recursion operates an end-to-end AI drug discovery platform spanning phenomics, generative chemistry, clinical operations, and partnerships with major pharmaceutical companies including Bayer, Roche/Genentech, and Sanofi. The company is headquartered in Salt Lake City, Utah and trades publicly on the Nasdaq Global Select Market under the ticker RXRX.
Recursion Pharmaceuticals is publicly traded
IPO'd on April 16, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under RXRX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2013
Employees
500–700
Total Funding
$435.5M
6 rounds
Last Private Valuation
$0.65B
September 9, 2020
Total raised $435.5M across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C
Date
July 15, 2019
Amount
$121M
Valuation
$0.65B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| September 9, 2020 | Series D | $239M | — | Leaps by Bayer |
| July 15, 2019 | Series C | $121M | $0.65B | Scottish Mortgage Investment Trust |
| October 4, 2017 | Series B | $60M | — | Data Collective |
Najat Khan
Chief Executive Officer & President
Chris Gibson
Co-Founder & Board Chair
Ben Taylor
President & Chief Financial Officer
David Hallett
Chief Scientific Officer
Kristen Rushton
Chief Operating Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Insilico Medicine
AI drug discovery platform (Pharma.AI) covering target discovery, generative chemistry, and clinical trial prediction; advanced first AI-discovered drug into Phase 2.
Schrodinger
Computational drug discovery company using physics-based molecular simulation and machine learning to design small molecules.
Absci
Generative AI biotech designing therapeutic antibodies de novo using deep learning combined with high-throughput wet-lab validation.
BenevolentAI
AI-driven drug discovery and development company using knowledge graph platform to identify novel targets and repurpose compounds.
Generate Biomedicines
Generative AI biotech designing novel proteins and biologics across multiple therapeutic modalities.
Valo Health
AI-powered drug discovery and development company using human-data-driven Opal platform to identify and advance therapeutics.
Yes, Recursion Pharmaceuticals is publicly traded under the ticker symbol RXRX on the NASDAQ. The company went public in April 16, 2021.
Recursion Pharmaceuticals trades under the ticker symbol RXRX on the NASDAQ. It began trading in April 16, 2021.
Recursion Pharmaceuticals (RXRX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker RXRX to place an order.
Recursion Pharmaceuticals went public in April 16, 2021 via ipo, with an offering valuation of approximately $0.65B. Recursion Pharmaceuticals priced its IPO on April 15, 2021 at $18.00/share and began trading on the Nasdaq Global Select Market under ticker RXRX on April 16, 2021, raising approximately $436M in gross proceeds. In November 2024, Recursion completed its all-stock combination with Exscientia plc, expanding its AI drug discovery platform with end-to-end capabilities.
Recursion Pharmaceuticals raised $435.5M across 6 disclosed funding rounds prior to its public listing.
Recursion Pharmaceuticals was founded by Chris Gibson in 2013.
Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.